Targeted delivery of paclitaxel and doxorubicin to cancer xenografts via the nanoparticle of nano-diamino-tetrac

Sudha T., Bharali D. J., Yalcin M., Darwish N. H. E., Coskun M. D., Keating K. A., ...Daha Fazla

INTERNATIONAL JOURNAL OF NANOMEDICINE, cilt.12, ss.1305-1315, 2017 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 12
  • Basım Tarihi: 2017
  • Doi Numarası: 10.2147/ijn.s123742
  • Dergi Adı: INTERNATIONAL JOURNAL OF NANOMEDICINE
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.1305-1315
  • Anahtar Kelimeler: doxorubicin, integrin, nanoparticle, Nanotetrac, NDAT, paclitaxel, tetraiodothy-roacetic acid, xenografts, ACTIVATED PROTEIN-KINASE, TETRAIODOTHYROACETIC ACID, THYROID-HORMONE, IN-VITRO, CO-DELIVERY, CELLS, NANOMEDICINE, RECEPTOR, GROWTH, CISPLATIN
  • Bursa Uludağ Üniversitesi Adresli: Evet

Özet

The tetraiodothyroacetic acid (tetrac) component of nano-diamino-tetrac (NDAT) is chemically bonded via a linker to a poly(lactic-co-glycolic acid) nanoparticle that can encapsulate anticancer drugs. Tetrac targets the plasma membrane of cancer cells at a receptor on the extracellular domain of integrin alpha v beta 3. In this study, we evaluate the efficiency of NDAT delivery of paclitaxel and doxorubicin to, respectively, pancreatic and breast cancer orthotopic nude mouse xenografts. Intra-tumoral drug concentrations were 5-fold (paclitaxel; P < 0.001) and 2.3-fold (doxorubicin; P < 0.01) higher than with conventional systemic drug administration. Tumor volume reductions reflected enhanced xenograft drug uptake. Cell viability was estimated by bioluminescent signaling in pancreatic tumors and confirmed an increased paclitaxel effect with drug delivery by NDAT. NDAT delivery of chemotherapy increases drug delivery to cancers and increases drug efficacy.